Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has issued a certificate in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming that securities received for dematerialization have been listed on the stock exchanges and the name of the depository has been substituted as the registered owner.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has completed the acquisition of Group Pharmaceuticals' wellness portfolio, a strategic move to strengthen its wellness portfolio and create opportunities for cross-selling its brands.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has published a newspaper advertisement regarding the transfer of shares to the Investor Education and Protection Fund (IEPF) and a notice of loss of share certificate. The company has sent individual notices to shareholders who have not claimed their dividend for seven consecutive years, requesting them to claim their shares by December 28, 2026. If no response is received, the company will transfer the shares to the IEPF authority.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has allotted 1,01,825 equity shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022 to eligible employees upon exercise of vested options, increasing the company's paid-up share capital from Rs. 13,19,14,840 to Rs. 13,21,18,490.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has closed its trading window for the quarter and six months ended September 30, 2026, in accordance with SEBI regulations and the company's code of conduct. The trading window will reopen 48 hours after the unaudited financial results are declared.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has entered into a Business Transfer Agreement with Group Pharmaceuticals Limited for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The acquisition is expected to strengthen the Company's pharmaceutical portfolio, expand its presence across therapeutic segments, and enhance market reach.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has entered into a Business Transfer Agreement with Group Pharmaceuticals Limited for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The acquisition is expected to strengthen the company's pharmaceutical portfolio, expand its presence across therapeutic segments, and enhance market reach.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has published a newspaper advertisement regarding the Notice of 47th Annual General Meeting and e-voting information in Business Standard (English) and Business Standard (Hindi) on August 28, 2026.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has announced the notice of its 47th Annual General Meeting (AGM) and Annual Report for the FY 2025-26. The AGM will be held on September 18, 2026, through video conferencing. The company has also provided the facility to vote by electronic means for all the resolutions set out in the AGM Notice. The record date for ascertaining the members of the Company for the purpose of payment of Dividend has been fixed for September 04, 2026.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has announced its Annual Report for FY 2025-26, including a 7% revenue growth, 5% CVM growth, and 19% operating PAT growth. The company has also declared a 200% dividend, including a special dividend of 75%. The report highlights the company's transformation over the past three financial years, including strengthening leadership depth, refining its portfolio, and embedding a sharper execution discipline.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has issued letters to shareholders providing a web link to access the Annual Report 2025-26, including the Notice of AGM, on the company's website. The AGM is scheduled to be held on September 18, 2026, through video conferencing.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has allotted 27,950 equity shares under the Employee Stock Option Plan 2022 to eligible employees upon exercise of vested options. The paid-up share capital of the company has increased from Rs. 13,18,58,940 to Rs. 13,19,14,840.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has announced the 47th Annual General Meeting (AGM) to be held on September 18, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company has published a newspaper advertisement in Business Standard (English) and Business Standard (Hindi) on August 12, 2026, as required by Regulation 30 of the SEBI (LODR) Regulations, 2015.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd announced Q1 FY27 earnings, with a 9% growth in sales, 21% growth in operating EBITDA, and 22% growth in net profits. The company acquired a controlling stake in Aequitas Healthcare for Rs.25 crores and completed a Rs.40 crores share buyback.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has made available the audio recording of its Q1 FY27 Earnings Conference Call held on July 30, 2026, for discussion of Q1 FY27 Financial Results on its website.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has published unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has announced changes in senior management personnel, designating Mr. Balmukund Keshav as Deputy General Manager (Information Technology) and Mr. Sanjay Singhal as General Manager (CQA & Regulatory Affairs), effective July 29, 2026.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has announced a record date of September 04, 2026, for determining entitlement to a proposed dividend of Rs. 4 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the 47th Annual General Meeting on September 18, 2026.

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has informed that the Nomination and Remuneration Committee has approved the grant of 1,20,000 employee stock options under Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022 at an exercise price of Rs. 179.25 per option.